Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
AIMS Public Health ; 9(2): 262-277, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35634019

RESUMEN

Since the inception of the current pandemic, COVID-19 related misinformation has played a role in defaulting control of the situation. It has become evident that the internet, social media, and other communication outlets with readily available data have contributed to the dissemination and availability of misleading information. It has perpetuated beliefs that led to vaccine avoidance, mask refusal, and utilization of medications with insignificant scientific data, ultimately contributing to increased morbidity. Undoubtedly, misinformation has become a challenge and a burden to individual health, public health, and governments globally. Our review article aims at providing an overview and summary regarding the role of media, other information outlets, and their impact on the pandemic. The goal of this article is to increase awareness of the negative impact of misinformation on the pandemic. In addition, we discuss a few recommendations that could aid in decreasing this burden, as preventing the conception and dissemination of misinformation is essential.

2.
Infect Chemother ; 53(2): 247-260, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-34216119

RESUMEN

BACKGROUND: The high rate of transmission and infection of coronavirus disease 2019 (COVID-19) is a public health emergency of major epidemiological concern. No definitive treatments have been established, and vaccinations have only recently begun. We aim to review the efficacy and safety of Interferon Beta (IFN-ß) in patients who have a confirmed COVID-19 diagnosis. MATERIALS AND METHODS: A search from PubMed, Science Direct, Cochrane, and Clinicaltrials.gov databases were conducted from December 2019 to December 2020 to review the efficacy and safety of IFN-ß in adult patients with COVID-19 confirmed. We included randomized controlled trials, case reports, and experimental studies. Correspondences, letters, editorials, reviews, commentaries, case control, cross-sectional, and cohort studies that did not include any new clinical data were excluded. RESULTS: Of the 66 searched studies, 8 were included in our review. These studies demonstrated that although IFN-ß did not reduce the time to clinical response, there was an increase in discharge rate at day 14 and a decrease in mortality at day 28. The time to negative reverse transcription polymerase chain reaction (RT-PCR) was shown to be significantly shortened in patients receiving IFN-ß, along with a lower nasopharyngeal viral load. Further, patients receiving IFN-ß had a less significant rise in IL-6. IFN-ß was shown to decrease intensive care unit (ICU) admission rate, the requirement of invasive ventilation in severe cases, and improve the survival rate compared to control groups. There were no severe adverse events reported. Our review found that patients who received early treatment with IFN-ß experienced significantly reduced length of hospitalization, mortality, ICU admission, and mechanical ventilation. A greater chance of clinical improvement and improved imaging studies was noted in patients who received IFN-ß. There were no reported deaths associated with the addition of IFN-ß. Further randomized trials involving more significant sample sizes are needed to better understand the effect of IFN-ß on survival in COVID-19. CONCLUSION: This review identified encouraging data and outcomes of incorporating IFN-ß to treat COVID-19 patients. IFN-ß has been shown to decrease hospital stay's overall length and decrease the severity of respiratory symptoms when added to the standard of care. Also, in some studies, it has been demonstrated to reduce the length of ICU stay, enhance survival rate, and decrease the need for invasive mechanical ventilation. There were minor side effects reported (neuropsychiatric symptoms and hypersensitivity reaction). However, randomized clinical trials with a large sample size are needed to assess IFN-ß's benefit precisely.

3.
Rev. argent. artrosc ; 2(3): 192-196, 1995. ilus
Artículo en Español | LILACS | ID: lil-347785

RESUMEN

Este articulo pretende mostrar en forma rapida, las 3 vias mas utilizadas en la artroscopia de la articulacion glenohumeral con sus reparos anatomicos. Ellas, le brindan al cirujano artroscopista utilidad, no solo en la exploracion diagnostica, sino tambien la posibilidad de desarrollar cualquier tecnica de reparacion


Asunto(s)
Artroscopía , Articulación del Hombro/cirugía , Diagnóstico
4.
Rev. argent. artrosc ; 2(3): 192-196, 1995. ilus
Artículo en Español | BINACIS | ID: bin-5426

RESUMEN

Este articulo pretende mostrar en forma rapida, las 3 vias mas utilizadas en la artroscopia de la articulacion glenohumeral con sus reparos anatomicos. Ellas, le brindan al cirujano artroscopista utilidad, no solo en la exploracion diagnostica, sino tambien la posibilidad de desarrollar cualquier tecnica de reparacion


Asunto(s)
Articulación del Hombro/cirugía , Artroscopía , Diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA